Market Closed -
Bombay S.E.
11:00:57 20/06/2024 BST
|
5-day change
|
1st Jan Change
|
52.48
INR
|
-2.81%
|
|
-4.06%
|
+42.61%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
380.7
|
518.8
|
927.1
|
1,796
|
1,779
|
1,538
|
Enterprise Value (EV)
1 |
564.7
|
823.9
|
1,301
|
2,283
|
2,231
|
2,118
|
P/E ratio
|
9.49
x
|
25.6
x
|
70.6
x
|
35.2
x
|
-48
x
|
-16.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.65
x
|
0.55
x
|
0.87
x
|
1.35
x
|
1.42
x
|
1.2
x
|
EV / Revenue
|
0.96
x
|
0.88
x
|
1.22
x
|
1.72
x
|
1.79
x
|
1.65
x
|
EV / EBITDA
|
12.2
x
|
14.4
x
|
26.1
x
|
27.4
x
|
380
x
|
-70.5
x
|
EV / FCF
|
-4.49
x
|
-11.7
x
|
-12.3
x
|
-15.5
x
|
39.6
x
|
-31.3
x
|
FCF Yield
|
-22.3%
|
-8.54%
|
-8.12%
|
-6.44%
|
2.53%
|
-3.19%
|
Price to Book
|
27.3
x
|
9.51
x
|
6.98
x
|
9.74
x
|
11.9
x
|
28.1
x
|
Nbr of stocks (in thousands)
|
7,385
|
14,594
|
46,354
|
47,313
|
47,313
|
47,313
|
Reference price
2 |
51.55
|
35.55
|
20.00
|
37.95
|
37.60
|
32.50
|
Announcement Date
|
03/09/18
|
05/09/19
|
06/09/20
|
02/09/21
|
07/09/22
|
09/09/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
587.1
|
939.2
|
1,063
|
1,327
|
1,249
|
1,285
|
EBITDA
1 |
46.16
|
57.27
|
49.75
|
83.29
|
5.866
|
-30.03
|
EBIT
1 |
40.42
|
46.62
|
33.86
|
64.68
|
-23.1
|
-62.75
|
Operating Margin
|
6.88%
|
4.96%
|
3.19%
|
4.87%
|
-1.85%
|
-4.88%
|
Earnings before Tax (EBT)
1 |
40.56
|
38.06
|
12.26
|
55.34
|
-50.18
|
-123.9
|
Net income
1 |
40.56
|
38.55
|
13.81
|
51.04
|
-37.03
|
-93.52
|
Net margin
|
6.91%
|
4.1%
|
1.3%
|
3.85%
|
-2.96%
|
-7.28%
|
EPS
2 |
5.430
|
1.390
|
0.2832
|
1.079
|
-0.7827
|
-1.980
|
Free Cash Flow
1 |
-125.9
|
-70.39
|
-105.7
|
-147.1
|
56.38
|
-67.59
|
FCF margin
|
-21.44%
|
-7.49%
|
-9.94%
|
-11.08%
|
4.51%
|
-5.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
961.16%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/09/18
|
05/09/19
|
06/09/20
|
02/09/21
|
07/09/22
|
09/09/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
184
|
305
|
374
|
488
|
452
|
580
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.986
x
|
5.326
x
|
7.514
x
|
5.856
x
|
77.12
x
|
-19.32
x
|
Free Cash Flow
1 |
-126
|
-70.4
|
-106
|
-147
|
56.4
|
-67.6
|
ROE (net income / shareholders' equity)
|
170%
|
47%
|
11.8%
|
32.1%
|
-22.2%
|
-91.9%
|
ROA (Net income/ Total Assets)
|
8.78%
|
4.71%
|
2.8%
|
4.2%
|
-1.34%
|
-3.4%
|
Assets
1 |
461.9
|
817.9
|
493
|
1,214
|
2,773
|
2,752
|
Book Value Per Share
2 |
1.890
|
3.740
|
2.860
|
3.900
|
3.150
|
1.150
|
Cash Flow per Share
2 |
0.5900
|
0.0600
|
0.0500
|
0.1200
|
0.0400
|
0.0400
|
Capex
1 |
20.2
|
25.8
|
90.1
|
136
|
35.8
|
28.1
|
Capex / Sales
|
3.45%
|
2.75%
|
8.48%
|
10.22%
|
2.87%
|
2.19%
|
Announcement Date
|
03/09/18
|
05/09/19
|
06/09/20
|
02/09/21
|
07/09/22
|
09/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +42.61% | 30.63M | | +51.75% | 803B | | -5.75% | 351B | | +19.52% | 324B | | +11.28% | 303B | | +16.96% | 243B | | +2.25% | 228B | | +11.15% | 217B | | +7.39% | 164B | | -3.35% | 155B |
Other Pharmaceuticals
|